{"id":"NCT01734928","sponsor":"Celgene","briefTitle":"Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma","officialTitle":"A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01-07","primaryCompletion":"2022-05-09","completion":"2022-05-13","firstPosted":"2012-11-28","resultsPosted":"2023-06-06","lastUpdate":"2023-06-06"},"enrollment":559,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"Pomalidomide","otherNames":["Oral Pomalidomide","CC-4047"]},{"type":"DRUG","name":"Bortezomib","otherNames":["Velcade"]},{"type":"DRUG","name":"Dexamethasone","otherNames":[]}],"arms":[{"label":"Pomalidomide, Bortezomib and Low Dose Dexamethasone","type":"EXPERIMENTAL"},{"label":"Bortezomib and Low Dose Dexamethasone","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the efficacy of the combination of pomalidomide, bortezomib and low dose dexamethasone to the combination of bortezomib and low dose dexamethasone in participants with relapsed/refractory multiple myeloma. This study will also assess how safe the combination of pomalidomide, bortezomib and low dose dexamethasone is compared to the combination of bortezomib and low dose dexamethasone.","primaryOutcome":{"measure":"Progression Free Survival by Independent Response Adjudication Committee (IRAC)","timeFrame":"From randomization to progressive disease or death during the IRAC assessment period, up to approximately 42 months","effectByArm":[{"arm":"Treatment 1: POM+BTZ+LD-DEX","deltaMin":11.2,"sd":null},{"arm":"Treatment 2: BTZ+LD-DEX","deltaMin":7.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":321,"countries":["United States","Austria","Canada","Denmark","Finland","France","Germany","Greece","Ireland","Israel","Italy","Japan","Netherlands","Norway","Poland","Portugal","Puerto Rico","Russia","Spain","Sweden","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["31097405","28642620"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/s/US/English/USenHome","https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":177,"n":278},"commonTop":["Peripheral sensory neuropathy","Thrombocytopenia","Diarrhoea","Neutropenia","Fatigue"]}}